Journals / Journal of Experimental and Clinical Medicine / 2025 / Volume: 42 Issue: 4

Pentraxin-3 in central nervous system infections: A promising but limited biomarker?

Berfin Çirkin Doruk(mersin şehir eğitim ve araştırma hastanesi)0000-0002-5370-4197
Yusuf Önlen(HATAY MUSTAFA KEMAL UNIVERSITY)0000-0002-8163-1386
Serdar Doğan(HATAY MUSTAFA KEMAL UNIVERSITY)0000-0001-6854-2197
Tayibe Bal(BOLU ABANT IZZET BAYSAL UNIVERSITY)0000-0002-5315-122X
Pages
—
Publication Date
2025-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The specific contribution of this study is that by evaluating both CSF and serum PTX3 levels simultaneously a relationship was determined between local and systemic inflammation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Central nervous system (CNS) infections lead to high morbidity and mortalitty rates, so there is a need for rapid and reliable biomarkers in diagnosis.
📊
Key Findings & Data:The aim of this study was to determine the diagnostic value of Pentraxin-3 (PTX3) levels in CNS infections and to compare these with classic parameters.
💡
Conclusion & Impact:The specific contribution of this study is that by evaluating both CSF and serum PTX3 levels simultaneously a relationship was determined between local and systemic inflammation.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Central nervous system infections · Pentraxin 3 · Cerebrospinal fluid

Abstract

Central nervous system (CNS) infections lead to high morbidity and mortalitty rates, so there is a need for rapid and reliable biomarkers in diagnosis. The aim of this study was to determine the diagnostic value of Pentraxin-3 (PTX3) levels in CNS infections and to compare these with classic parameters. The study included 42 adult patients diagnosed with CNS infection between July 2020 and August 2021. The cerebral spinal fluid (CSF) and serum PTX3 levels were measured with the ELISA method. The findings were compared with clinical and laboratory parameters. The diagnostic performance was evaluated with ROC curve analysis. Bacterial meningitis was diagnosed in 39.0% of the patients, viral encephalitis in 51.2%, tuberculous meningitis in 7.3%, and fungal meningitis in 2.4%. The mortality rate was determined to be 43.9%. The CSF PTX3 levels were found to be higher in the bacterial cases, but with no significant difference between the serum and CSF PTX3 levels (p=0.327). A negative correlation was determined between CSF PTX3 and the Glasgow Coma Score, and a positive correlation between CSF PTX3 and the CSF protein level. In the ROC analyses, the strongest parameters for differentiation of bacterial and aseptic meningitis were seen to be CSF cell count (AUC: 0.888) and PMN percentage (AUC:0.882, while CSF PTX3 (AUC:0.586) and serum PTX3 (AUC:0.561) had the lowest differentiating power. PTX3 can be measured in CNS infections and higher levels are seen in bacterial meningitis cases. However, according to the ROC analysis results the diagnostic power is limited and these parameters lag behind classic CSF parameters. Therefore, PTX3 alone is not sufficient, but when combined with other biomarkers it can contribute to the clinical diagnostic process. The specific contribution of this study is that by evaluating both CSF and serum PTX3 levels simultaneously a relationship was determined between local and systemic inflammation.

🔖

Cite This Article

Doruk, B. Ç., Önlen, Y., Doğan, S., Bal, T. (2025). Pentraxin-3 in central nervous system infections: A promising but limited biomarker?. Journal of Experimental and Clinical Medicine, Volume: 42 Issue: 4. https://ajindex.com/articles/1422546

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Brindle HE, Choisy M, Christley R, et al. The global burden of central nervous system infections: a modelling study. Front Public Health. 2024;12:1371502. doi:10.3389/fpubh.2024.1371502
  2. van Zeggeren IE, ter Horst L, Heijst H, Teunissen CE, van de Beek D, Brouwer MC. Neurofilament light chain in central nervous system infections: a prospective study of diagnostic accuracy. Sci Rep. 2022;12(1):14140. doi:10.1038/s41598-022-18450-9
  3. Giuliano S, Flammini S, Giacobbe DR, et al. Role of procalcitonin and C-reactive protein in patients with bacterial meningitis. Eur J Clin Microbiol Infect Dis. 2022;41(3):387-94. doi:10.1007/s10096-021-04358-8
  4. Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64(6):1416-27. doi:10.1016/j.jhep.2016.02.029
  5. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-66. doi:10.1146/annurev.immunol.23.021704.115756
  6. Bonacina S, Barbieri SS, Cutuli L, et al. Pentraxin 3 in cardiovascular and neuroinflammatory disorders. Front Immunol. 2022;13:841095. doi:10.3389/fimmu.2022.841095
  7. Zatta M, Di Pietro A, D'Abramo A, et al. Cerebrospinal fluid pentraxin 3 in patients with meningitis: diagnostic and prognostic significance. Eur J Clin Microbiol Infect Dis. 2020;39(4):665-70. doi:10.1007/s10096-019-03759-7
  8. El-Kady H, Mostafa MG, Hassan R, et al. Cerebrospinal fluid pentraxin 3 as a biomarker for bacterial meningitis in children. BMC Pediatr. 2025;25(1):7. doi:10.1186/s12887-024-05065-1
  9. Porte R, Davoudian S, Asgari F, et al. The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate diagnostic/prognostic biomarker in infectious and inflammatory diseases. Front Immunol. 2019;10:794. doi:10.3389/fimmu.2019.00794
  10. Thomsen MM, Munthe-Fog L, Garred P, et al. Pentraxin 3 levels in cerebrospinal fluid as a diagnostic marker of bacterial meningitis. PLoS One. 2023;18(3):e0282004. doi:10.1371/journal.pone.0282004
  11. Hamed GM, Megahed NA, Abdelhakeem G, et al. Plasma pentraxin 3 in patients with sepsis: relationship with severity and outcome. BMC Infect Dis. 2017;17:554. doi:10.1186/s12879-017-2663-0.